OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01. Other Events.
On March 20, 2017, OWC Pharmaceutical Research Corp. (“OWC”)
issued a press release announcing the promising preliminary
results from the efficacy testing of its cannabinoid-based
topical cream for treating psoriasis, reporting significant
reduction of several inflammation markers specific to psoriasis.
OWC announced that it anticipates that the topical cream will be
market-ready during 2017 Q2 and, subject to regulatory approvals
from applicable jurisdictions, the topical cream should be
available for use by those who suffer from psoriasis in the near
Reference is made to the full text of the press release filed as
Exhibit 99.1 herewith.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.
|99.1||Press Release dated March 20, 2017, filed herewith.|
About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system. OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Recent Trading Information
OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) closed its last trading session up +0.01 at 1.30 with 1,883,919 shares trading hands.